{"name":"Alfred E. Tiefenbacher (GmbH & Co. KG)","slug":"alfred-e-tiefenbacher-gmbh-co-kg","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dorzolamide 2 % eye drops solution","genericName":"Dorzolamide 2 % eye drops solution","slug":"dorzolamide-2-eye-drops-solution","indication":"Glaucoma","status":"phase_3"}]}],"pipeline":[{"name":"Dorzolamide 2 % eye drops solution","genericName":"Dorzolamide 2 % eye drops solution","slug":"dorzolamide-2-eye-drops-solution","phase":"phase_3","mechanism":"Dorzolamide inhibits carbonic anhydrase II in the eye to reduce aqueous humor production and lower intraocular pressure.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPc2l1ZVBpMXpwaXpmOWxEc1BSOUhuSjVtSEswMU5EOTMxWHV0NHVwdHFmTmJsZGxsWlJMWjdBRmpRbWIyTmNIN3VKYmVvTGpHNTRoT01WUHR4QnJlYng1dUdLT25PQWViWnZYRzhWSmRucmtRdnNvQTBvcVNJb2JCVlN3NzFSYm8zY1k2TzBaTjdnY2YwUl9WaVhJNFpZMHdLZ1lTZGpWRWQ4TUF1YzBKMzFkWQ?oc=5","date":"2022-04-22","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022 - European Medicines ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}